Editorial: Synthetic peptide vaccine platforms targeting tumor-specific antigens: advances and challenges

Reid M Rubsamen; Andrew E Sloan

doi:10.3389/fphar.2024.1363282

Editorial: Synthetic peptide vaccine platforms targeting tumor-specific antigens: advances and challenges

Front Pharmacol. 2024 Feb 23:15:1363282. doi: 10.3389/fphar.2024.1363282. eCollection 2024.

Authors

Reid M Rubsamen^{1

2}, Andrew E Sloan³

Affiliations

¹ School of Medicine, Case Western Reserve University, Cleveland, OH, United States.
² University Hospitals Cleveland Medical Center, Cleveland, OH, United States.
³ Piedmont Healthcare, Atlanta, GA, United States.

No abstract available

Keywords: ELISpot assay; MHC binding affinity prediction; TCR sequencing; immunogenicity; peptide vaccine; synthetic vaccines; toll like receptor (TLR); tumor specific antigens.

Publication types

Editorial

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.